1
|
Nissen-Meyer LSH, Steinsvåg TT, Fenstad MH, Sørvoll IH, Hvalryg M, Titze TL, Magnussen K, Kristoffersen G, Johnsen KMN, Llohn AH, Hermundstad B, Høiback LS, Haugen M, Kristoffersen EK, Boulland LML, Kran AMB, Lund-Johansen F, Vaage JT, Flesland Ø, Hervig TA. Convalescent plasma from Norwegian blood donors to treat COVID-19. TIDSSKRIFT FOR DEN NORSKE LEGEFORENING 2023; 143:22-0180. [PMID: 37589362 DOI: 10.4045/tidsskr.22.0180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/18/2023] Open
Abstract
BACKGROUND At the start of the pandemic, the Norwegian Directorate of Health and Norwegian blood banks initiated the production of COVID-19 convalescent plasma within the framework of clinical studies. In this article we describe the blood donors who participated. MATERIAL AND METHOD Blood donors who had recovered from COVID-19 were recruited to donate single donor plasma for the purpose of patient treatment. Data on the course of infection, leukocyte antibodies and antibody level against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) per plasma unit were registered after informed consent was obtained. We calculated a disease score defined as the total number of self-reported symptoms/findings and hospitalisation where relevant (score 0-11). RESULTS A total of 1644 plasma units were collected from 266 plasma donors at 12 blood banks. Median disease score was 5 (interquartile range 3-6), and 15 donors had recovered from pneumonia and/or been hospitalised. A total of 599/1644 plasma units from 106/266 donors met our requirement for SARS-CoV-2 antibody content (> 60 % inhibition of virus binding to angiotensin-converting enzyme 2 (ACE2)) or positive virus neutralisation test. The antibody level in donors waned over time following infection, and showed no clear correlation with disease score. INTERPRETATION The number of symptoms and findings in blood donors could not predict antibody response at individual level, and antibody testing was crucial for the production of effective convalescent plasma.
Collapse
Affiliation(s)
| | | | | | - Ingvild Hausberg Sørvoll
- Nasjonal behandlingstjeneste for avansert trombocyttimmunologi, Laboratoriemedisin, Universitetssykehuset Nord-Norge
| | - Marte Hvalryg
- Immunologisk og transfusjonsmedisinsk avdeling, Akershus universitetssykehus
| | | | - Karin Magnussen
- Avdeling for blodbank og medisinsk biokjemi, Sykehuset Innlandet
| | | | | | - Abid Hussain Llohn
- Immunologisk og transfusjonsmedisinsk avdeling, Akershus universitetssykehus
| | - Brita Hermundstad
- Seksjon for komponentfremstilling, Immunologisk og transfusjonsmedisinsk avdeling, Akershus universitetssykehus
| | | | - Morten Haugen
- Avdeling for blodbank og medisinsk biokjemi, Sykehuset Innlandet
| | - Einar K Kristoffersen
- Avdeling for immunologi og transfusjonsmedisin, Laboratorieklinikken, Haukeland universitetssjukehus, og, Klinisk institutt 2, Universitetet i Bergen
| | - Line M L Boulland
- Seksjon for transplantasjonsimmunologi, Avdeling for immunologi og transfusjonsmedisin, Oslo universitetssykehus
| | | | | | - John Torgils Vaage
- Avdeling for immunologi og transfusjonsmedisin, Oslo universitetssykehus
| | - Øystein Flesland
- Avdeling for kvalitetsforbedring og pasientsikkerhet, Helsedirektoratet
| | - Tor Audun Hervig
- Irish Blood Transfusion Service, Dublin, og, Trinity College, Dublin
| |
Collapse
|
2
|
Kamo-Imai A, Togano T, Sato M, Kawakami Y, Inaba K, Shimazu H, Igarashi S, Tanaka K, Terada M, Kinoshita-Iwamoto N, Saito S, Kutsuna S, Hangaishi A, Morioka S, Takahashi K, Miyata S, Ohmagari N. The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan. Transfus Apher Sci 2023:103687. [PMID: 36964059 PMCID: PMC10027293 DOI: 10.1016/j.transci.2023.103687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 02/23/2023] [Accepted: 02/27/2023] [Indexed: 03/24/2023]
Abstract
PURPOSE Since 2020, the novel coronavirus infection (COVID-19) has spread globally. A few studies have investigated the safety of COVID-19 convalescent plasma (CCP) apheresis from COVID-19. This study was the first retrospective observational study of CCP in Japan. METHODS We recruit donors from April 2020 to November 2021 and plasmapheresis in our center (NCGM: national center for global health and medicine). We set the primary endpoint as the Donors Adverse Event (DAE) occurrence at the time of the CCP collection. Variable selection was used to explore the determinants of DAE. RESULTS Mean and SD age was 50.5 (10.6) years old. Seventy-three (42.2 %) were female, and 87 (33.3 %) were multiple-times donors. Twelve (6.97 % by donors and 4.6 % in total collections) adverse events occurred. The DAEs were VVR (Vaso Vagal Reaction), paresthesia, hypotension, agitation, dizziness, malaise, and hearing impairment/paresthesia. Half of them were VVR during apheresis. DAE occurred only in first-time donors and more in severe illnesses such as using ventilation and ECMO. From the donor characteristics and variable selection, the risk factors are as follows: younger age, female, the severity of disease at the time of the disease, and lower SBP before initiation. Our DAE incidence did not differ from previous studies. DAEs were more likely to occur in CCP apheresis than in healthy donors. CONCLUSION We confirm the safety of CCP apheresis in this study, although DAEs were more than healthy donors. More caution should be exercised in the plasma collection for future outbreaks of emerging infectious diseases.
Collapse
Affiliation(s)
- Ayumi Kamo-Imai
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Teikyo University Graduate School of Public Health, Tokyo, Japan
| | - Tomiteru Togano
- Department of Hematology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
| | - Motohiko Sato
- Department of Clinical Engineering, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Yuiko Kawakami
- Department of Clinical Engineering, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Kumi Inaba
- Department of Clinical Engineering, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Hiroshi Shimazu
- Department of Hematology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Saori Igarashi
- Department of Nursing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Keiko Tanaka
- Department of Nursing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Mari Terada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - Noriko Kinoshita-Iwamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Satoshi Kutsuna
- Department of Infection Control, Graduate School of Medicine, Osaka University, Japan
| | - Akira Hangaishi
- Department of Hematology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Kenzo Takahashi
- Teikyo University Graduate School of Public Health, Tokyo, Japan
| | - Satoshi Miyata
- Teikyo University Graduate School of Public Health, Tokyo, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
3
|
Crowder LA, Steele WR, Goodhue E, Lasky B, Young PP. COVID-19 convalescent plasma donors: Unique motivations in unique times? Transfusion 2023; 63:703-710. [PMID: 36866426 DOI: 10.1111/trf.17298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 02/01/2023] [Accepted: 02/01/2023] [Indexed: 03/04/2023]
Abstract
BACKGROUND Early in the SARS-CoV-2 pandemic, many blood collection organizations (BCOs) were asked to collect and distribute COVID-19 convalescent plasma (CCP) as a potential treatment for this new virus and resulting disease. However, recruiting CCP donors presented unique challenges for BCOs, as there were few recovered patients at this time, and like the general population, most potential CCP donors had no blood donation experience. Thus, many CCP donors were new donors, and their donation motivations were unknown. MATERIALS AND METHODS Donors who gave CCP at least once between April 27th and September 15th, 2020, were emailed a link to an online survey regarding their experience with COVID-19 and their motivations for donating CCP and blood. RESULTS Of the 14,225 invitations sent, 3471 donors responded (24.4%). Most donors had never donated blood before (n = 1406), followed by lapsed donors (n = 1050), and recent donors (n = 951). There was a significant relationship between self-reported donation experience and fear of CCP donation (X2 = 119.2, p < .001). Motivations ranked "very important" by responding donors were wanting to help someone in need, a feeling of responsibility, and feeling a duty to donate. Donors with more severe disease were more likely to respond with feelings of a sense of duty to donate CCP (Χ2 = 8.078, p = .044) or altruism (Χ2 = 8.580, p = .035). CONCLUSIONS Overwhelmingly, altruism and a sense of duty and responsibility were the reasons that CCP donors decided to donate. These insights can be useful for motivating donors for specialized donation programs or if wide scale CCP recruitment is needed in the future.
Collapse
Affiliation(s)
| | | | | | - Baia Lasky
- American Red Cross, Rockville, Maryland, USA
| | | |
Collapse
|
4
|
Van Buren NL, Rajbhandary S, Reynolds V, Gorlin JB, Stramer SL, Notari EP, Conti G, Katz L, Stubbs JR, van Buskirk CM, Kuttner K, Smith DL, Ngamsuntikul SG, Pandey S, Ward DC, Ziman A, Hiskey M, Townsend M, Sachais BS. Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors. Transfusion 2023; 63:552-563. [PMID: 36550639 PMCID: PMC9880744 DOI: 10.1111/trf.17229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/30/2022] [Accepted: 12/01/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Previous studies have demonstrated low first-time donor return rates (DRR) following catastrophic events. Little is known, however, about the influence of demographic factors on the DRR of first-time donors during the COVID-19 pandemic, including the unique motivation of COVID-19 convalescent plasma (CCP) donors as compared to non-CCP donors. STUDY DESIGN AND METHODS Thirteen blood collection organizations submitted deidentified data from first-time CCP and non-CCP donors returning for regular (non-CCP) donations during the pandemic. DRR was calculated as frequencies. Demographic factors associated with returning donors: race/ethnicity, gender, and generation (Gen Z: 19-24, Millennial: 25-40, Gen X: 41-56, and Boomer: ≥57 years old), within the CCP and non-CCP first-time cohorts were compared using chi-square test at p < .05 statistical significance. RESULTS From March 2020 through December 2021, there were a total of 44,274 first-time CCP and 980,201 first-time non-CCP donors. DRR were 14.6% (range 11.9%-43.3%) and 46.6% (range 10.0%-76.9%) for CCP and non-CCP cohorts, respectively. Age over 40 years (Gen X and Boomers), female gender, and White race were each associated with higher return in both donor cohorts (p < .001). For the non-CCP return donor cohort, the Millennial and Boomers were comparable. CONCLUSION The findings demonstrate differences in returning donor trends between the two donor cohorts. The motivation of a first-time CCP donor may be different than that of a non-CCP donor. Further study to improve first-time donor engagement would be worthwhile to expand the donor base with a focus on blood donor diversity emphasizing engagement of underrepresented minorities and younger donors.
Collapse
Affiliation(s)
- Nancy L. Van Buren
- Division of New York Blood CenterInnovative Blood ResourcesSaint PaulMinnesotaUSA
- Division of New York Blood CenterCommunity Blood Center of Greater Kansas CityKansas CityMissouriUSA
| | | | - Vanessa Reynolds
- Division of New York Blood CenterInnovative Blood ResourcesSaint PaulMinnesotaUSA
| | - Jed B. Gorlin
- Division of New York Blood CenterInnovative Blood ResourcesSaint PaulMinnesotaUSA
- Division of New York Blood CenterCommunity Blood Center of Greater Kansas CityKansas CityMissouriUSA
| | | | | | - Galen Conti
- Scientific AffairsAmerican Red CrossRockvilleMarylandUSA
| | | | - James R. Stubbs
- Division of Transfusion Medicine, Department of Laboratory Medicine and PathologyMayo ClinicRochesterMinnesotaUSA
| | - Camille M. van Buskirk
- Division of Transfusion Medicine, Department of Laboratory Medicine and PathologyMayo ClinicRochesterMinnesotaUSA
| | - Kip Kuttner
- Miller‐Keystone Blood CenterBethlehemPennsylvaniaUSA
| | | | | | | | - Dawn C. Ward
- Division of Transfusion Medicine, Department of Pathology and Laboratory MedicineDavid Geffen School of Medicine at UCLALos AngelesCaliforniaUSA
| | - Alyssa Ziman
- Division of Transfusion Medicine, Department of Pathology and Laboratory MedicineDavid Geffen School of Medicine at UCLALos AngelesCaliforniaUSA
| | | | | | | |
Collapse
|
5
|
Perenc L, Pęczkowski R. Knowledge and Attitudes of Young Adults Towards Donation of COVID-19 Convalescent Plasma and Its Therapeutic Properties. J Blood Med 2021; 12:709-717. [PMID: 34408520 PMCID: PMC8364396 DOI: 10.2147/jbm.s319652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 06/30/2021] [Indexed: 11/30/2022] Open
Abstract
PURPOSE The aim of this study is to investigate the level of knowledge of the young adults towards the possible use of the convalescent plasma (CP) in the treatment of COVID-19 infection and their attitudes towards its donation. METHODS Cross-sectional questionnaire was administered online to 1058 university students, representing 4 different colleges. The questionnaire included demographic data and 20 questions related to the knowledge and attitudes of respondents about possible use of the convalescent plasma in the treatment of COVID-19 infection and its donation. Comparative analyses were made using the Mann-Whitney and Kruskal-Wallis tests and the Spearman correlation coefficient. RESULTS Significant relationships were found between dependent variables (level of knowledge and intensity of attitude) and gender, age, and student's college affiliation. There was no statistically significant correlation between dependent variables and respondents' social background and religious commitment. Studied young adults show a satisfactory knowledge relating to the therapeutic and preventive properties of the COVID-19 convalescent plasma. They also express a sufficient intensity of positive attitude towards CP donation. CONCLUSION This study confirms the need for appropriate health promotional campaigns and educational programs aimed at popularization of CP donation in the general public, which would increase the chances of involving more patients recovered from COVID-19 disease.
Collapse
Affiliation(s)
- Lidia Perenc
- Institute of Health Sciences, University of Rzeszow, Rzeszow, 35-310, Poland
| | | |
Collapse
|
6
|
Cho JH, Rajbhandary S, van Buren NL, Fung MK, Al-Ghafry M, Fridey JL, Dy BA, Ziman A, Schreiber GB, Gammon RR, Reik R, Stubbs JR, van Buskirk CM, Kamel H, Townsend MJ, Zeller MP, Gottschall JL. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study. Transfusion 2021; 61:2668-2676. [PMID: 34227689 PMCID: PMC8447310 DOI: 10.1111/trf.16572] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 06/14/2021] [Accepted: 06/14/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND Although the safety and therapeutic efficacy of COVID-19 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi-institutional context. STUDY DESIGN AND METHODS Nine blood collection organizations (BCOs) participated in a multi-institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity. RESULTS The overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis-naïve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5-17.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions. CONCLUSION The safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.
Collapse
Affiliation(s)
- Joseph H Cho
- Medical Sciences Institute, Versiti, Milwaukee, Wisconsin, USA
| | | | - Nancy L van Buren
- Innovative Blood Resources, Division of New York Blood Center, St. Paul, Minnesota, USA
| | - Mark K Fung
- Department of Pathology and Laboratory Medicine, The University of Vermont Health Network, Burlington, Vermont, USA
| | | | - Joy L Fridey
- American Red Cross Blood Services, Southern California Region, Pomona, California, USA
| | - Beth A Dy
- American Red Cross Biomedical Services, Washington, District of Columbia, USA
| | - Alyssa Ziman
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
| | | | - Richard R Gammon
- Scientific, Medical, Technical Direction, OneBlood, Orlando, Florida, USA
| | - Rita Reik
- Scientific, Medical, Technical Direction, OneBlood, Orlando, Florida, USA
| | - James R Stubbs
- Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | - Camille M van Buskirk
- Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | | | | |
Collapse
|
7
|
Jain S, Garg K, Tran SM, Rask IL, Tarczon M, Nandi V, Kessler DA, Strauss D, Sachais BS, Yazdanbakhsh K, Rehmani S, Luchsinger L, Shi PA. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area. Transfusion 2021; 61:2374-2383. [PMID: 33904609 PMCID: PMC8242807 DOI: 10.1111/trf.16421] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 04/11/2021] [Accepted: 04/12/2021] [Indexed: 12/11/2022]
Abstract
Background Convalescent plasma (CP) is an important initial treatment in pandemics and the New York (NY) metropolitan area is likely to remain a hotspot for collection and distribution of such units. This study reports characteristics of coronavirus disease 19 CP (CCP) donors and their donations to the New York Blood Center (NYBC). Study design and methods All CCP data from our first day of collection on March 26th through July 7th, 2020 are included in this retrospective analysis. Donor and donation data were extracted from NYBC electronic databases. SARS‐CoV‐2 antibody testing was initially performed by the NY State Department of Health, and later by NYBC using Ortho and Abbott platforms. Results CCP donor age and ABO distributions were consistent with reported lower COVID‐19 susceptibility in O blood types. CCP versus whole blood donors had similar on‐site deferrals, but higher post‐donation deferral rates. CCP versus routine plasmapheresis donations had higher vasovagal reactions but similar product rejection rates. Changes in antibody (Ab) test platforms resulted in significant changes in the percent of donors regarded as antibody positive. Donor correlates with higher anti‐spike total Ig S/CO ratios were Hispanic ethnicity, overweight body mass index, and longer symptom duration; and with higher anti‐nucleocapsid IgG S/CO ratios were male gender, older age, Hispanic ethnicity, and fewer days between symptom onset and first donation. Discussion We identify donor characteristics not previously reported to correlate with Ab titer. Our analysis should assist with donor outreach strategies, blood center operating logistics, and recruitment of high titer donors.
Collapse
Affiliation(s)
- Saagar Jain
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Keshav Garg
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Sabrina M Tran
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Isabel L Rask
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Michael Tarczon
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Vijay Nandi
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Debra A Kessler
- Clinical Services, New York Blood Center, New York, New York, USA
| | - Donna Strauss
- Clinical Services, New York Blood Center, New York, New York, USA
| | - Bruce S Sachais
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.,Clinical Services, New York Blood Center, New York, New York, USA
| | - Karina Yazdanbakhsh
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Shiraz Rehmani
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Larry Luchsinger
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
| | - Patricia A Shi
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.,Clinical Services, New York Blood Center, New York, New York, USA
| |
Collapse
|
8
|
Kamel H. We stand ready … Blood collection organizations and the COVID-19 pandemic. Transfusion 2021; 61:1345-1349. [PMID: 33966274 PMCID: PMC8207090 DOI: 10.1111/trf.16400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Accepted: 04/04/2021] [Indexed: 12/14/2022]
Abstract
See article on page 1471–1478, in this issue
Collapse
|